BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11761222)

  • 1. TRIPs revisited.
    Ford N
    Br J Gen Pract; 2001 Nov; 51(472):948. PubMed ID: 11761222
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and intellectual property rights.
    Correa CM
    Bull World Health Organ; 2001; 79(5):381. PubMed ID: 11417031
    [No Abstract]   [Full Text] [Related]  

  • 4. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 5. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 6. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 7. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
    Childs DW
    Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
    [No Abstract]   [Full Text] [Related]  

  • 9. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
    Curti AM
    Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
    [No Abstract]   [Full Text] [Related]  

  • 10. Compulsory licensing for bridging the gap - treatment access in developing countries: interview with James Love, Consumer Project on Technology. Interview by John S. James.
    Love J
    AIDS Treat News; 1999 Mar; (No 314):1-7. PubMed ID: 11366241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential conflict between TRIPS and GATT concerning parallel importation of drugs and possible solution to prevent undesirable market segmentation.
    Lo CF
    Food Drug Law J; 2011; 66(1):73-83, ii. PubMed ID: 24505847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 16. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 17. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

  • 18. [On misery coast. Episode 1: the market of vital drugs].
    Chneiweiss H
    Med Sci (Paris); 2003; 19(8-9):892-4. PubMed ID: 14593623
    [No Abstract]   [Full Text] [Related]  

  • 19. Undermining TRIPS: protectionism at its worst.
    Lancet; 2007 Jan; 369(9555):2. PubMed ID: 17208619
    [No Abstract]   [Full Text] [Related]  

  • 20. Scrooge and intellectual property rights.
    Stiglitz JE
    BMJ; 2006 Dec; 333(7582):1279-80. PubMed ID: 17185703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.